NCT07029230 Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.
| NCT ID | NCT07029230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Martin Schweiger |
| Condition | Congenital Heart Surgery |
| Study Type | OBSERVATIONAL |
| Enrollment | 225 participants |
| Start Date | 2025-09-10 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 225 participants in total. It began in 2025-09-10 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
Eligibility Criteria
Inclusion Criteria: * Consented for cardiopulmonary bypass surgery for cardiac reason * Conversational skills in German (by child and/or representative) to be able to fully understand and sign a written consent in German language Exclusion Criteria: * Know genetic life limiting conditions * Syndrome patients who are scheduled or highly likely to be operated on more than one organ * Body weight at time of surgery less than 2.5 kg * Being recruited and enrolled for an interventional study protocol
Contact & Investigator
Martin Schweiger, Prof, MD, MBA
PRINCIPAL INVESTIGATOR
University Children's Hospital, Zurich
Frequently Asked Questions
Who can join the NCT07029230 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Congenital Heart Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07029230 currently recruiting?
Yes, NCT07029230 is actively recruiting participants. Contact the research team at sst2@kispi.uzh.ch for enrollment information.
Where is the NCT07029230 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT07029230 clinical trial?
NCT07029230 is sponsored by Martin Schweiger. The principal investigator is Martin Schweiger, Prof, MD, MBA at University Children's Hospital, Zurich. The trial plans to enroll 225 participants.